PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Group: 1646

Ligensa, et al.

Examiner: J. Andres

Serial No. 09/453,195, filed December 2, 1999

For: IGF-1 RECEPTOR INTERACTING PROTEINS

DECLARATION OF MICHAEL WEIDNER UNDER 37 C.F.R. §1.132

Commissioner for Patents
Washington, D.C. 20231

Sir:

I, Michael Weidner, a citizen of Germany, declare as follows, that:

In 1991 I received a Ph. D in Cell Biology summa cum laude from the University of Essen, Essen, Germany.

From 1991 through 1993 I did postdoctoral research at the Institute of Cell Biology at the University of Essen, Essen Germany and the Institute of Cell Biology at the Max-Delbrück-Center for Molecular Medicine, Berlin, Germany, and received the "Falcon Preis" awarded by theGerman Society for Cell Biology for work done during this period.

Since November 1996 I have been employed by Hoffmann-La Roche Ltd. as Senior Scientist in the Department of Oncology and Department of Molecular Biology, Penzberg, Germany. My research is in the area of molecular mechanisms of tumor development and progression, with regard to signal transduction, growth factors, tyrosine kinases, and adhesion molecules, using recombinant cell systems, gene discovery, protein biochemistry, and yeast two-hybrid technology.

I am an inventor of the claimed nucleic acids which encode the protein IIP-10 which binds to the IGF-1 receptor. This Declaration is submitted to demonstrate that IIP-10 binds to and inhibits the activity of the IGF-1 receptor.

To make this demonstration, the following experiments of Examples 1 and 2 were carried out under my supervision and control.

Examples

Example 1:

The IGF-1 receptor stimulates tumor cell proliferation. IIP-10 expression inhibits this proliferation in IGF-1 receptor overexpressing NIH-3T3 cells which stably express IIP-10.

Example 2:

The IGF-1 receptor protects tumor cells from Fas-induced apoptosis. IIP-10 expression reduces the level of protection accordingly increasing apoptosis in IGF-1 receptor overexpressing NIH-3T3 cells which stably express IIP-10.

Materials

NIH-3T3 fibroblast clones which overexpress the human IGF-1 receptors and therefore have acquired the characteristics of tumor cells: 10/2, 10a/12, 10a/19, 10a/20, H2, and H3.

Clones stably transfected with IIP-10: 10/2, 10a/12, 10a/19, and 10a/20.

Clones not transfected with IIP-10 (mock transfected clones): H2, H3

Methods

Example 1: IIP-10 inhibition of IGF-1 induced stimulation of proliferation in IGF-1 receptor overexpressing NIH3T3 cells:

Four IGF-1R overexpressing NIH3T3 clones stably transfected with IIP-10 (10/2, 10a/12,

10a/19, 10a/20) and two mock transfected clones (H2, H3) were plated in serum containing medium at a density of 5 x 10^3 cells/well in a 96-well microtiter plate. After 24h the growth medium was removed and replaced with serum free medium (SFM) containing 0.5% dialyzed FCS. After serum starvation for 24h, the cells were stimulated with 50ng/ml IGF-1 in SFM containing 0.5% dialyzed FCS for 48h. For monitoring cell proliferation cells were labeled with BrdU (Roche Molecular Biochemicals) for 24h. After the labeling-period a Cell Proliferation ELISA (Roche Molecular Biochemicals) quantifying the incorporated BrdU was performed according to the manufacturers protocol. In Figure1, the ordinate gives the percent increase in BrdU incorporation after IGF-1 stimulation compared to SFM containing 0.5% dialyzed FCS. As can be seen in Figure 1, H2 and H3 cells showed about 250% and about 375% proliferation, respectively. In contrast, the 10/2, 10a/12, 10a/19, and 10/20 cells showed about 150%, 75%, 100%, and 100% proliferation, respectively.

Example 2: IIP-10 inhibition of IGF-1 mediated protection of fas induced apoptosis in IGF-1 receptor overexpressing NIH3T3 cells:

One IGF-1R overexpressing NIH3T3 clone stably expressing IIP-10 (10/2) and one mock transfected clone (H2) were plated in serum containing medium at a density of 5x10^3 cells/well in a 96-well microtiter plate. After 24h, Fas-mediated apoptosis was induced by the addition of 70ng/ml recombinant human FasL (Alexis, CA, USA) and 1µg/ml Enhancer (Alexis, CA, USA) in serum free medium (SFM) containing 0.5% dialyzed FCS. At the same time IGF-1 was added in a concentration of 10^{-8}M to protect cells from Fas-induced apoptosis. After 16h the amount of apoptotic cells was quantified using the Cell Death Detection ELISA^{PLUS} (Roche Molecular Biochemicals) according to the manufacturers protocol. As can be seen in Figure2, about 50% of 10/2 cells suffered apoptosis. In contrast, only about 25% of H2 cells suffered apoptosis.

Conclusion

These results demonstrate that the protein IIP-10 inhibits the action of the IGF-1 receptor in cells which express the IGF-1 receptor.

Example 1 shows that IIP-10 expression reduces proliferation in tumor cells. IIP-10-transfected tumor cell clones showed from 100% to 300% less proliferation than non IIP-10-transfected tumor cell clones. The IGF-1 receptor, when active, promotes tumor cell proliferation. Therefore the ability of IIP-10 to inhibit the activity of the receptor reduces proliferation.

Example 2 shows that IIP-10 expression increases apoptosis in tumor cells. Fas-mediated apoptosis eliminated twice as many IIP-10-transfected tumor cell clones than non IIP-10-transfected tumor cell clones. The IGF-1 receptor, when active, can protect tumor cells from apoptosis. Therefore the ability of IIP-10 to inhibit the activity of the receptor reduces protection from apoptosis and gives rise to more apoptosis.

These results indicate that inhibition of IGF-1 receptor activity has negative effects on tumor cells, reducing their ability to proliferate and increasing their vulnerability to apoptosis. Therefore, the ability of IIP-10 to inhibit the activity of the IGF-1 receptor indicates that IIP-10 has antitumor activity.

In addition, the more IIP-10 is present in a tumor cell, the less likely is the cell to metastasize, since IIP-10 reduces the ability of tumor cells to proliferate. Therefore the IIP-10 level found in a given tumor cell is related to its metastatic potential.

I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 23.04.01

Michael Weidner

109586

Publications:

Keilhack H., M Müller, SA Böhmer, C Frank, KM Weidner, W Birchmeier, T Ligensa, A Berndt, H.Kosmehl, B. Günther, T. Müller, C. Birchmeier, FD. Böhmer. Negative Regulation of Ros Receptor Tyrosine Kinase Signaling - an Epithelial Function of the SH2 Domain Protein-Tyrosine Phosphatase SHP-1. *J.Cell Biol.*, **in press**

Stefan M., A. Koch, A. Mancini, A. Mohr, K.M Weidner, H. Niemann and T. Tamura (2000). The SH-2-containing inositol 5`phosphatase (SHIP)-1 binds to the mutifunctional docking site of c-Met and potentiates the hepatocyte-growth factor (HGF) induced branching tubologenesis. *J. Biol. Chem.*, **2000 Nov 7 [epub ahead of print]**

Vayssiere B, G Zalcman, Y Mahe, G Mirey, T Ligensa, KM Weidner, P Chardin, and J Camonis (2000) Interaction of the Grb7 adapter protein with Rnd1, a new member of the Rho family. *FEBS Lett*, **467**, 91-96

Tamura, T., A. Mancini, H. Joos, A. Koch, C. Hakim, J.Dumanski, K.M Weidner and H. Niemann (1999). FMIP, a novel Fms-interacting protein, affects granulocyte/macrophage differentiation. *Oncogene,* **18**: 6488-6495

Simins AB, H.Weighardt, KM Weidner, UH Weidle and B.Holzmann (1999). Functional cloning of ARM-1, an adhesion-regulating molecule upregulated in metastatic tumor cells. *Clin. Exp. Metastasis.*, **17**: 641-649

Tulasne, D., R. Paumelle, KM Weidner, B. Vandenbunder and V. Fafeur (1999). The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering. *Mol Biol Cell.* **10**:551-65.

Bai, R.Y., T. Jahn, S. Schrem, G. Munzert, K.M. Weidner, J.Y. Wang and J. Duyster (1998). The SH2-containing adapter protein GRB10 interacts with BCR-ABL. *Oncogene* **17**: 941-948.

Jeffers, M., G.A. Taylor, K.M. Weidner, S. Omura and G.F. VandeWoude (1997). Degradation of the met tyrosine kinase receptor by the ubiquitin-proteasome pathway. *Mol. Cell. Biol.*, **17**: 799-808.

Weidner, K.M., S Di Cesare, M. Sachs, V. Brinkmann, J. Behrens and W. Birchmeier (1996). Interaction between Gab1 and the c-Met receptor tyrosine kinases is responsible for epithelial morphogenesis. *Nature*, **384**: 173-176.

Sachs, M., K. M. Weidner, A. Obermeier, A. Ullrich and W. Birchmeier (1996). Morphogenic and Motogenic Activity of Various Epithilial Receptor Tyrosine Kinases. *J. Cell Biol.*, **133**: 1095-1107.

Isakoff, S.J., Y. Yu, Y-C. Su, P. Blaikie, V.Yajnik, K.M. Weidner, M. Sachs, B. Margolis and E.Y. Skolnik (1996). The PTP/PI domain of shc is required for shc phosphorylation by the insulin receptor (IR) and recognizes an NPXY motif that is distinct from IRS-1. *J Biol. Chem.*, **271**: 3959-3962.

Birchmeier, W., J. Behrens, K.M. Weidner and J.Hülsken (1996). Epithelial differentiation and the control of metastasis in carcinomas. In: *Attempts to understand metastasis formation.* U. Günthert and W. Birchmeier eds., Springer Verlag, CTMI 213/II.

Weidner, K.M., M. Sachs and W. Birchmeier (1995). Mutation of juxtamembrane tyrosine residue 1001 supresses loss-of-function mutations of the met receptor in epithelial cells. *Proc. Natl. Acad. Sci. USA*, **92**: 2597-2601.

Yang, Y., E. Spitzer, D. Meyer, M. Sachs, C. Niemann, G. Hartmann, K.M. Weidner, C. Birchmeier and W. Birchmeier (1995). Sequential requirements of hepatocyte growth factor and neuregulin in the morphogenesis of the mammary gland. *J. Cell. Biol.*, **131**: 215-226.

Brinkmann, V., M. Sachs, K.M. Weidner and W. Birchmeier (1995). Scatter factor/hepatocyte growth factor induces tissue-specific morphogenic programs in epithelial cells. *J. Cell Biol.*, **131**:1573-1586.

Volk, A., G. Michalopoulos, M.Weidner. and R.Gebhardt (1995), Different proliferative responses of periportal and pericentral rat hepatocytes to hepatocyte growth factor. *Biochem, Biophys. Res. Commun.*, **207**: 578-584.

Hartmann, G., K.M. Weidner, H. Schwarz and W. Birchmeier (1994). The motility signal of scatter factor/hepatocyte growth factor mediated through the receptor tyrosine kinase met requires intracellular action of ras. *J. Biol. Chem.*, **269**: 21936-21939

Weidner, K.M., G. Hartmann, L. Naldini, P.M. Comoglio, M. Sachs, C. Fonatsch, H. Rieder and W. Birchmeier (1993). Molecular characteristics of HGF-SF and its role in cell motility and invasion. In: *Hepatocyte growth factor - scatter factor (HGF-SF) and the c-Met receptor*, I.D. Goldberg ed., Birkhäuser Verlag, Basel, 312-328.

Sonnenberg E., K.M. Weidner and C. Birchmeier (1993). Expression of the met-receptor and HGF-SF during mouse embryogenesis. In: *Hepatocyte growth factor - scatter factor (HGF-SF) and the cMet receptor*, I.D. Goldberg ed., Birkhäuser Verlag, Basel, 382-394.

Birchmeier, C., E. Sonnenberg, B. Walter and K.M. Weidner (1993). Tyrosine kinase receptors in the control of epithelial growth and morphogenesis during development. *BioEssays*, **15**: 185-190.

Weidner, K.M., M. Sachs and W. Birchmeier (1993). The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor / hepatocyte growth factor in epithelial cells. *J. Cell Biol.*, **11**:145-154.

Sonnenberg, E., D. Meyer, K.M. Weidner, W. Birchmeier und C. Birchmeier (1993). Scatter

factor/hepatocyte growth factor and its receptor, the c-met tyrosine-kinase, mediate a signal exchange between mesenchyme and epithelia during mouse development. *J. Cell Biol.*,**123**: 223-235.

Weidner, K.M., G. Hartmann, M. Sachs and W. Birchmeier (1993). Properties and functions of scatter factor / hepatocyte growth factor and its receptor c-Met. *Am. J. Respir. Cell Mol. Biol.*, **8**: 229-237.

Birchmeier, W., K.M. Weidner., J. Hülsken,. and J. Behrens (1993). Molecular mechanisms leading to cell junction (cadherin) deficiency in invasive carcinomas *Semin. Cancer Biol.* **4**: 231-239.

Birchmeier, W., K.M. Weidner., and J. Behrens (1993). Molecular mechanisms leading to loss of differentiation and gain of invasiveness in epithelial cells. *J. Cell Sci.*, **17**: 159-164.

Behrens, J., U. Frixen, J. Schipper, K.M. Weidner and W. Birchmeier (1992). Cell adhesion in invasion and metastasis. Seminars in Cell Biology, **3**: 169-178

Birchmeier, W., K.M. Weidner and J. Behrens (1992). Molecular aspects of the invasion of carcinoma cells. In: *Metastasis: Basic research and its clinical applications*, Rabes, H., P.E. Peters and K. Munk eds., Contrib. Oncol. Basel, Karger, **44**: 95-107

Hartmann, G., L. Naldini, K.M. Weidner, M. Sachs, E. Vigna, P.M. Comoglio and W. Birchmeier (1992). A functional domain in the heavy chain of scatter factor / hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. *Proc. Natl. Acad. Sci. USA*, **89**:11574-11578.

Weidner, K.M., N. Arakaki, J. Vandekerckhove, S. Weingart, G. Hartmann, H. Rieder, C. Fonatsch, H. Tsubouchi, T. Hishida, Y. Daikuhara and W. Birchmeier (1991). Evidence for the identity of human scatter factor and human hepatocyte growth factor. *Proc. Natl. Acad. Sci. USA.* **88**: 7001-7005.

Naldini, L., K.M. Weidner, E. Vigna, G. Gaudino, A. Bardelli, C. Ponzetto, R.P. Narsimhan, G. Hartmann, R. Zarnegar, G.K. Michalopoulos, W. Birchmeier and P.M. Comoglio (1991). Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. *EMBO Journal* **10**: 2867-2878.

Behrens, J., K.M. Weidner, U. Frixen, J.H. Schipper, M. Sachs and W. Birchmeier (1991). The role of E-cadherin and scatter factor in tumor invasion and cell motility. In: *Cell motility factors*, I.D. Goldberg ed., Birkhäuser Verlag, Basel, 109-126.

Birchmeier, W., J. Behrens, K.M. Weidner, U.H. Frixen and J. Schipper (1991). Dominant and recessive genes involved in tumor cell invasion. Current Opinions in Cell Biol. **3**: 832-840.

Birchmeier, W., J. Behrens, K.M. Weidner, U. Frixen, M. Sachs and J. Vendekerckhove (1991). Molecular and cellular aspects of tumor cell invasion. In: *Origins of human cancer: a comprehensive review*. Cold Spring Harbour Laboratory Press, Cold Spring Harbour, 587-599.

Weidner, K.M., J. Behrens, J. Vandekerckhove and W. Birchmeier (1990). Scatter factor:

molecular characteristics and effect on the invasiveness of epithelial cell. *J. Cell Biol.*, **111**: 2097-2108.